Background Pt-reported outcomes (PRO) are used to assess pt-related benefit in clinical trials. Inflammatory arthritis (IA) pts are equally receptive to intravenous (IV) or subcutaneous (SC) biologic treatment1.
Objectives We obtained PRO data to understand characteristics of pts who receive IV biologic agents for IA.
Methods This was a questionnaire-based study conducted at a rheumatology practice with extensive clinical trial experience. A total of 100 pts enrolled & are included in this final analysis. Inclusion criteria: a diagnosis of IA with IV biologic use for ≥3 mo; ≥18 yrs age; able to read, write & speak English, willing to complete the questionnaire & a signed informed consent form. IV biologic treatment was per clinical practice; there were no treatment assignments & study drug was not supplied. The questionnaire had 30 questions which pts completed prior to receiving a regularly scheduled dose of IV biologic.
Results Mean (±SD) age of pts was 58.35 (±14.64) yrs with mean disease duration of 10.1 (±8.13) yrs (range 0.7–45 years). Pts were Caucasian (38%), African American (28%), Latino/Hispanic (22%), Asian/Pacific Islander (1%) & 11% not identified. IV biologics used were infliximab [IFX](71%), rituximab [RTX](12%), tocilizumab [TCZ](10%), abatacept [ABT](6%) & golimumab [GLM](1%). The mean duration of current IV therapy was 4.07 (±3.27) yrs (range 0.1 to 16.0 yrs). Pts' favorability perception of IV therapy BEFORE & AFTER starting IV therapy is shown in the Figure. Amongst all pts, “Extremely favorable” increased (p<0.05) from 33% to 71% after receiving IV therapy; the increase in “Extremely favorable” was evident in pts with or without previous SC biologic therapy. Of the 33% of pts reporting an “Extremely favorable” rating BEFORE starting IV therapy, 6% changed their opinion to a lesser rating AFTER starting therapy, whereas 44% of patients reporting “Extremely favorable” AFTER starting IV therapy had indicated a lesser rating BEFORE starting IV therapy.
Conclusions These results suggest that among IA pts receiving IV biologic therapy for treatment of IA, there is a high degree of pt satisfaction, including a similar favorability perception of IV therapy among pts who switched from a SC to an IV biologic. Our results support the concept that when there is a shared decision making discussion with pts regarding biologic treatments, the option of IV therapy should be an essential part of that discussion & that the IA pts' perspective should be given meaningful consideration.
Bolge SC et al Arthritis Rheum 2013;65 Suppl 10:1023
Disclosure of Interest N. Gaylis Grant/research support from: Janssen Scientific Affairs, LLC, J. Sagliani Grant/research support from: Janssen Scientific Affairs, LLC, S. Black Employee of: Janssen R & D, LLC, K. Tang Employee of: Janssen R & D, LLC, R. Dehoratius Employee of: Janssen Scientific Affairs, LLC, D. Parenti Employee of: Janssen Scientific Affairs, LLC
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.